NCT03835884 - A Study Assessing AR-13503 Implant in Subjects With nAMD or DME | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 24, 2019

Primary Completion Date

May 12, 2022

Study Completion Date

May 12, 2022

Conditions

Neovascular Age-related Macular DegenerationDiabetic Macular Edema

Interventions

DRUG

AR-13503 Implant 10.6 Dose

AR-13503 Implant 10.6 Dose (10.6 µg) administered as an intravitreal implant into a single eye

DRUG

AR-13503 Implant 21.2 Dose

AR-13503 Implant 21.2 Dose (21.2 µg) administered as intravitreal implants into a single eye

DRUG

AR-13503 42.4 Dose

AR-13503 Implant 42.4 Dose (42.4 µg) administered as intravitreal implants into a single eye

DRUG

AR-13503 63.6 Dose

AR-13503 Implant 63.6 Dose (63.6 µg) administered as intravitreal implants into a single eye

Trial Locations (6)

Medical Center Ophthamology Associates, San Antonio

Valley Retina Institute, P.A., Harlingen

Retinal Research Institute, LLC, Gilbert

Retina-Vitreous Associates Medical Group, Beverly Hills

Bay Area Retina Associates, Walnut Creek

Sterling Vision, PC dba Oregon Retina, Eugene